News & Updates

Show Multimedia Only
Bile acid reductions with odevixibat tied to improved LFTs in patients with PFIC2
Bile acid reductions with odevixibat tied to improved LFTs in patients with PFIC2
16 Jul 2026 byAudrey Abella

In individuals receiving odevixibat for progressive familial intrahepatic cholestasis 2 (PFIC2), also known as bile salt export pump (BSEP) deficiency, reductions in serum bile acid (sBA) levels correlated with improvements in key liver function tests (LFTs), according to a post hoc subgroup analysis presented at ESPGHAN 2026.

Bile acid reductions with odevixibat tied to improved LFTs in patients with PFIC2
16 Jul 2026
Do multivitamin supplements prevent COVID-19 incidence?
Do multivitamin supplements prevent COVID-19 incidence?
15 Jul 2026
Functional outcome improvements with atogepant sustained until 3 years
Functional outcome improvements with atogepant sustained until 3 years
15 Jul 2026 byAudrey Abella

A 156-week safety extension study presented at EAN 2026 shows the first 3-year long-term results for atogepant in the preventive treatment of migraine in individuals with chronic migraine (CM) or episodic migraine (EM) who had an insufficient response to 2–4 classes of conventional oral, non-migraine-specific preventive migraine treatments.

Functional outcome improvements with atogepant sustained until 3 years
15 Jul 2026